Why is Beryl Drugs falling/rising?

As of 09-Sep, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at 24.12, reflecting a decrease of 0.73 or 2.94%. The stock has underperformed its sector by 3.57% today, and its delivery volume has significantly decreased by 39.97% compared to the 5-day average, indicating falling investor participation. Over the past week, the stock has dropped by 5.96%, while it has shown a notable increase of 24.65% over the past month. However, the stock's long-term performance remains concerning, with a staggering decline of 45.14% over the past year, despite a relatively attractive valuation based on its ROCE of 11 and trading at a discount compared to peers.
In the broader market context, the Sensex has shown a positive return of 1.18% over the past week and 1.56% over the past month, contrasting sharply with Beryl Drugs' recent performance. The stock's weak long-term fundamentals, characterized by a low average ROCE of 7.27% and poor growth in net sales and operating profit, further exacerbate its struggles. Additionally, the company's ability to service its debt is weak, which has contributed to its underperformance relative to the market, as evidenced by the negative returns of -2.87% in the last year for the broader BSE500 index.